

PI Major Mutations: None
PI Accessory Mutations: None
PR Other Mutations: I13V ^{100%}_{class=2,202} • E35D ^{100%}_{class=2,965} • M36I ^{100%}_{class=2,965} • R41K ^{100%}_{class=2,208} • R57K ^{100%}_{class=2,875} • D60E ^{100%}_{class=2,287} • H69K ^{100%}_{class=2,285} • L89M ^{100%}_{class=2,129}

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

No drug resistance mutations were found for PI.

NRTI Mutations: None
NNRTI Mutations: [V106I](#) ^{100%}_{class=205}
RT Other Mutations: E6D ^{100%}_{class=2,038} • V21I ^{100%}_{class=1,823} • V35T ^{100%}_{class=1,231} • T39A ^{100%}_{class=1,287} • V50I ^{100%}_{class=157} • V118I ^{100%}_{class=757} • K122E ^{100%}_{class=802} • K173A ^{100%}_{class=2,008} • Q174K ^{100%}_{class=2,008} • D177E ^{100%}_{class=2,582} • V179I ^{100%}_{class=2,558} • T200A ^{100%}_{class=1977} • Q207E ^{100%}_{class=1791} • R211S ^{100%}_{class=522} • F214L ^{100%}_{class=503}

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Potential Low-Level Resistance
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Potential Low-Level Resistance
didanosine (DDI)	Susceptible	nevirapine (NVP)	Potential Low-Level Resistance
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Potential Low-Level Resistance
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

RT comments

NNRTI

- V106I** occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility only in combination with other NNRTI-resistance mutations. It is commonly selected in persons receiving DOR in combination with mutations at position 227.

Other

- V118I** is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs.
- V179I** is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

Download CSV

▼

Rule	DOR ⚡	EFV ⚡	ETR ⚡	NVP ⚡	RPV ⚡
V106I	10	0	10	10	10